Peri- and Post-Approval Services
Forward. Faster. Further.
Today’s world of drug development is constantly changing. With an increase in patient engagement and empowerment, a rise in new real-world data sources and a shifting stakeholder and regulatory landscape, you need a way to break through the chaos to find clarity so patients can get what they need.
Evidera, PPD’s dedicated peri- and post-approval business, brings together innovative methodologies, cutting-edge technologies and unparalleled experts with a passion for creating solutions. With over 35 years of scientific rigor and operational expertise, we can help you take on Phase I to post-launch with unmatched efficiency and speed. Ready to move your product forward?
- Simulate impact of changes to sample size and duration on potential outcomes through modeling and advanced statistical methods
- Create synthetic control arms when placebo is not logistically, financially, or humanistically possible
- Leading an IMPACT HTA work package to create guidance on the combination of RCT results with RWE (observational, registry) in economic evaluation
- First CRO to join MIT’s NEWDIGS initiative as a strategic partner
- First successful implementation of a real-world data collection framework add-on to an Early Access to Medicines Schemes (EAMS) program
Access Insight from Evidera experts
Our researchers are prolific producers of scientific content. Browse Evidera’s library of white papers, webinars, fact sheets and issues of our biannual publication, The Evidence Forum.